No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
www.bachem.comNo one on the platform currently holds BANB.SW.
No tracked institution reports a position in BANB.SW as of their last filing.
No one on the platform has traded BANB.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.6% | 9.9% | 10.3% | — | — | — |
| Rev. Growth % | 14.8% | 11.6% | ||||
| Profit Margin % | 21.4% | 20.5% | 18.9% | |||
| Free Cash Flow Margin % | -6.9% | -9.3% | -3.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $942M | +37.5% | $2.40 | $2.23–$2.72 | — | 8 |
| 2027 | $1.2B | +22.6% | $3.01 | $2.80–$3.35 | — | 8 |
| 2028 | $1.4B | +18.1% | $3.58 | $3.14–$3.90 | — | 6 |
| 2029 | $1.6B | +13.8% | $4.17 | $3.90–$4.49 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $0.47 | $0.67 | +43.3% |
| 2026-03-12 | $0.92 | $1.32 | +43.0% |
| 2025-07-24 | $0.51 | $0.67 | +31.0% |
| 2025-02-27 | $1.17 | $1.12 | -4.3% |
| 2024-07-25 | $0.39 | $0.48 | +23.1% |
| 2023-07-27 | $0.48 | $0.46 | -4.2% |
| 2023-03-07 | $0.98 | $0.87 | -11.3% |
| +1.66% |
| $18.6B |
| — |
| GURN.SWGurit Holding AG | $54.40 | -2.51% | $254M | — |
| ZWM.SWZwahlen & Mayr S.A. | $144.00 | +0.00% | $10M | — |
Source: Financial Modeling Prep · peers by sector/industry